Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

被引:0
|
作者
Montalban-Bravo, Guillermo [1 ]
Short, Nicholas J. [1 ]
Chien, Kelly S. [1 ]
Valero, Yesid Alvarado [1 ]
Daver, Naval [1 ]
Borthakur, Gautam [1 ]
Swaminathan, Mahesh [1 ]
Maiti, Abhishek [2 ]
Hammond, Danielle E. [1 ]
Nogueras-Gonzalez, Graciela [3 ]
Huang, Xuelin [3 ]
Schneider, Heather [4 ]
Shelly, Kristen [4 ]
Kadia, Tapan M. [1 ]
Kantarjian, Hagop M. [4 ]
Garcia-Manero, Guillermo [5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
关键词
D O I
10.1182/blood-2023-178035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    Kadia, Tapan M.
    Reville, Patrick K.
    Wang, Xuemei
    Rausch, Caitlin R.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval G. G.
    DiNardo, Courtney D. D.
    Sasaki, Koji
    Issa, Ghayas C. C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J. J.
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N. N.
    Jabbour, Elias
    Takahashi, Koichi
    Malla, Rashmi
    Quagliato, Kelly
    Kanagal-Shamanna, Rashmi
    Popat, Uday R. R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina Y. Y.
    Ravandi, Farhad
    Kantarjian, Hagop M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3848 - +
  • [2] Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
    Vinod Pullarkat
    Keith W. Pratz
    Hartmut Döhner
    Christian Recher
    Michael J. Thirman
    Courtney D. DiNardo
    Pierre Fenaux
    Andre C. Schuh
    Andrew H. Wei
    Arnaud Pigneux
    Jun-Ho Jang
    Gunnar Juliusson
    Yasushi Miyazaki
    Dominik Selleslag
    Martha L. Arellano
    Chenglong Liu
    Jean A. Ridgeway
    Jalaja Potluri
    Jovita Schuler
    Marina Konopleva
    Blood Cancer Journal, 15 (1)
  • [3] Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
    Montalban-Bravo, Guillermo
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval Guastad
    Ravandi, Farhad
    Borthakur, Gautam
    Takahashi, Koichi
    Andreeff, Michael
    Cortes, Jorge E.
    Dinardo, Courtney Denton
    Jabbour, Elias
    Kadia, Tapan M.
    Kornblau, Steven
    Ohanian, Maro
    Huang, Xuelin
    Nogueras-Gonzalez, Graciela M.
    Bodden, Kristy
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study
    Li, Yanyan
    Zhou, Haixia
    Wan, Chaoling
    Xu, Mingzhu
    Qian, Chongsheng
    Zhang, Tongtong
    Dai, Haiping
    Sun, AiNing
    Wu, Depei
    Xue, Shengli
    BLOOD, 2022, 140 : 3212 - 3213
  • [5] Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [6] Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose- escalation, dose-expansion, phase 1-2 study
    Bazinet, Alexandre
    Darbaniyan, Faezeh
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Chien, Kelly
    Kadia, Tapan
    Takahashi, Koichi
    Masarova, Lucia
    Short, Nicholas
    Alvarado, Yesid
    Yilmaz, Musa
    Ravandi, Farhad
    Andreeff, Michael
    Kanagal-Shamanna, Rashmi
    Ganan-Gomez, Irene
    Colla, Simona
    Qiao, Wei
    Huang, Xuelin
    McCue, Deborah
    Mirabella, Bailey
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    LANCET HAEMATOLOGY, 2022, 9 (10): : E756 - E765
  • [7] Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study
    Bataller, Alex
    Sasaki, Koji
    Urrutia, Samuel
    Montalban-Bravo, Guillermo
    Bazinet, Alexandre
    Chien, Kelly
    Hammond, Danielle
    Bouligny, Ian M.
    Swaminathan, Mahesh
    Issa, Ghayas
    Short, Nicholas
    Daver, Naval
    DiNardo, Courtney D.
    Kadia, Tapan
    Jabbour, Elias
    Ravandi, Farhad
    Roboz, Gail J.
    Savona, Michael
    Griffiths, Elizabeth A.
    McCloskey, James
    Odenike, Olatoyosi
    Oganesian, Aram
    Keer, Harold N.
    Azab, Mohammad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [8] PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Zeidan, A. M.
    Garcia, J.
    Fenaux, P.
    Platzbecker, U.
    Miyazaki, Y.
    Xiao, Z.
    Zhou, Y.
    Naqvi, K.
    Kye, S.
    Manero, G. Garcia
    LEUKEMIA RESEARCH, 2021, 108 : S47 - S47
  • [9] Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Morita, Kiyomi
    Naqvi, Kiran
    Montalban, Guillermo
    Thompson, Philip A.
    Takahashi, Koichi
    Alvarado, Yesid
    Jabbour, Elias
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [10] Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
    Ottmann, Oliver G.
    DeAngelo, Daniel J.
    Garcia-Manero, Guillermo
    Luebbert, Michael
    Jillella, Anand
    Sekeres, Mikkael A.
    Zahlten, Anita
    Squier, Margaret
    Acharyya, Suddhasatta
    Winiger, Ivo J.
    Fenaux, Pierre
    BLOOD, 2011, 118 (21) : 212 - 213